X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (3880) 3880
Publication (285) 285
Book Review (40) 40
Book Chapter (12) 12
Conference Proceeding (8) 8
Magazine Article (5) 5
Dissertation (3) 3
Book / eBook (1) 1
Data Set (1) 1
Web Resource (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (3310) 3310
pyridones - therapeutic use (2570) 2570
index medicus (2246) 2246
male (1588) 1588
female (1393) 1393
pyridones - pharmacology (923) 923
animals (916) 916
pyridones - administration & dosage (898) 898
middle aged (823) 823
pyrazoles - therapeutic use (788) 788
pyridones - adverse effects (778) 778
aged (772) 772
adult (743) 743
administration, oral (659) 659
treatment outcome (659) 659
anticoagulants - therapeutic use (648) 648
pharmacology & pharmacy (609) 609
rivaroxaban (587) 587
dabigatran (568) 568
anticoagulants (442) 442
iron chelating agents - therapeutic use (429) 429
apixaban (423) 423
warfarin (423) 423
hematology (406) 406
atrial fibrillation - drug therapy (398) 398
stroke - prevention & control (374) 374
pyrazoles - adverse effects (343) 343
atrial fibrillation (330) 330
deferiprone (326) 326
adolescent (324) 324
mice (319) 319
pyrazoles - administration & dosage (315) 315
analysis (314) 314
anticoagulants - adverse effects (313) 313
warfarin - therapeutic use (310) 310
morpholines - therapeutic use (307) 307
care and treatment (305) 305
atrial fibrillation - complications (298) 298
medicine, general & internal (298) 298
pyridones - pharmacokinetics (294) 294
rats (292) 292
thiophenes - therapeutic use (288) 288
benzimidazoles - therapeutic use (286) 286
dose-response relationship, drug (286) 286
pyridones - chemistry (286) 286
aged, 80 and over (283) 283
beta-alanine - analogs & derivatives (283) 283
drug therapy (280) 280
hemorrhage - chemically induced (279) 279
cardiac & cardiovascular systems (277) 277
anticoagulants - administration & dosage (273) 273
therapy (273) 273
oncology (268) 268
milrinone (266) 266
safety (266) 266
stroke (266) 266
drug therapy, combination (264) 264
deferoxamine - therapeutic use (257) 257
abridged index medicus (248) 248
efficacy (247) 247
pirfenidone (244) 244
anti-inflammatory agents, non-steroidal - therapeutic use (242) 242
risk factors (240) 240
prevention (233) 233
rivaroxaban - therapeutic use (231) 231
idiopathic pulmonary fibrosis - drug therapy (217) 217
research (214) 214
venous thromboembolism (211) 211
beta-alanine - therapeutic use (210) 210
young adult (208) 208
biochemistry & molecular biology (207) 207
clinical trials as topic (206) 206
child (203) 203
pyridines - therapeutic use (203) 203
dabigatran - therapeutic use (197) 197
cancer (196) 196
randomized controlled trials as topic (196) 196
time factors (196) 196
clinical trials (190) 190
peripheral vascular disease (190) 190
stroke - etiology (190) 190
medicine & public health (186) 186
respiratory system (182) 182
thromboembolism (182) 182
pharmacokinetics (181) 181
iron overload - drug therapy (180) 180
retrospective studies (180) 180
factor xa inhibitors - therapeutic use (178) 178
double-blind (177) 177
cell line, tumor (176) 176
double-blind method (176) 176
deferoxamine (175) 175
antifungal agents - therapeutic use (171) 171
melanoma - drug therapy (169) 169
management (168) 168
atrial-fibrillation (166) 166
heart failure - drug therapy (165) 165
clinical neurology (162) 162
beta-thalassemia - drug therapy (159) 159
chemistry, medicinal (159) 159
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (3604) 3604
German (84) 84
French (46) 46
Spanish (43) 43
Italian (28) 28
Japanese (24) 24
Russian (14) 14
Czech (7) 7
Swedish (7) 7
Chinese (6) 6
Polish (6) 6
Bulgarian (4) 4
Danish (4) 4
Finnish (3) 3
Hungarian (3) 3
Dutch (2) 2
Hebrew (2) 2
Croatian (1) 1
Norwegian (1) 1
Portuguese (1) 1
Serbian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Thrombosis and Haemostasis, ISSN 0340-6245, 09/2015, Volume 113, Issue 5, pp. 931 - 942
Summary Several new anticoagulants have entered the clinical arena or are under clinical development. These drugs include indirect (fondaparinux) and direct... 
Review Article | Rivaroxaban | Antidotes | Dabigatran | New anticoagulants | Apixaban | ANDEXANET-ALPHA | VITAMIN-K ANTAGONISTS | rivaroxaban | apixaban | ATRIAL-FIBRILLATION | antidotes | IN-VITRO | ANTIIDIOTYPIC ANTIBODIES | PROTHROMBIN COMPLEX CONCENTRATE | ORAL ANTICOAGULANTS | MOLECULAR-WEIGHT HEPARIN | dabigatran | PERIPHERAL VASCULAR DISEASE | HEALTHY-VOLUNTEERS | HEMATOLOGY | ACUTE VENOUS THROMBOEMBOLISM | Recombinant Proteins - therapeutic use | Pyrazoles - therapeutic use | Anticoagulants - administration & dosage | Thrombosis - complications | Humans | Antibodies, Monoclonal - therapeutic use | Heparin - therapeutic use | Hemorrhage - prevention & control | Thiazoles - therapeutic use | Dabigatran - therapeutic use | Vitamin K - antagonists & inhibitors | Benzamides - therapeutic use | Anticoagulants - chemistry | Factor Xa - therapeutic use | Intracranial Hemorrhages - prevention & control | Rivaroxaban - therapeutic use | Pyridines - therapeutic use | Polysaccharides - therapeutic use | Hemostatics - chemistry | Antibodies, Monoclonal, Humanized - therapeutic use | Administration, Oral | Antithrombins - therapeutic use | Infusions, Parenteral | Clinical Trials as Topic | Factor Xa Inhibitors - therapeutic use | Animals | Protamines - therapeutic use | Pyridones - therapeutic use | Thrombosis - drug therapy | Hemorrhage - chemically induced | Hemostatics - therapeutic use
Journal Article
Circulation, ISSN 0009-7322, 07/2016, Volume 134, Issue 3, pp. 248 - 261
Vitamin K antagonists are commonly used by clinicians to provide anticoagulation to patients who have or are at risk of having thrombotic events. In addition... 
anticoagulants | atrial fibrillation | venous thromboembolism | hemorrhage | CARDIAC & CARDIOVASCULAR SYSTEMS | ACTIVATED FACTOR-VII | ATRIAL-FIBRILLATION | IN-VITRO | THROMBIN GENERATION | DABIGATRAN ETEXILATE | PROTHROMBIN COMPLEX CONCENTRATE | SYMPTOMATIC VENOUS THROMBOEMBOLISM | PRACTICAL MANAGEMENT | PERIPHERAL VASCULAR DISEASE | STAGE RENAL-DISEASE | FACTOR XA INHIBITOR | Recombinant Proteins - therapeutic use | Plasma | Dabigatran - adverse effects | Pyrazoles - therapeutic use | Humans | Hemorrhage - prevention & control | Recombinant Proteins - adverse effects | Thiazoles - therapeutic use | Factor VIIa - therapeutic use | Arginine - analogs & derivatives | Dabigatran - therapeutic use | Thiazoles - adverse effects | Pyridines - adverse effects | Rivaroxaban - adverse effects | Factor Xa - therapeutic use | Rivaroxaban - therapeutic use | Factor Xa - adverse effects | Pyrazoles - adverse effects | Pyridines - therapeutic use | Antibodies, Monoclonal, Humanized - therapeutic use | Administration, Oral | Antithrombins - therapeutic use | Piperazines - therapeutic use | Dabigatran - antagonists & inhibitors | Piperazines - adverse effects | Factor Xa Inhibitors - therapeutic use | Hemorrhage - drug therapy | Antithrombins - adverse effects | Factor Xa Inhibitors - adverse effects | Blood Coagulation Factors - therapeutic use | Arginine - adverse effects | Pyridones - therapeutic use | Hemorrhage - chemically induced | Hemostatics - therapeutic use | Arginine - therapeutic use | Pyridones - adverse effects
Journal Article
Circulation, ISSN 0009-7322, 07/2007, Volume 116, Issue 5, pp. 552 - 560
fondaparinux | CARDIAC & CARDIOVASCULAR SYSTEMS | bivalirudin | STROKE PREVENTION | myocardial infarction | INITIAL TREATMENT | heparin | ST-ELEVATION | PERCUTANEOUS CORONARY INTERVENTION | ORTHOPEDIC-SURGERY | MOLECULAR-WEIGHT HEPARIN | anticoagulants | mortality | ACUTE MYOCARDIAL-INFARCTION | PERIPHERAL VASCULAR DISEASE | enoxaparin | NONVALVULAR ATRIAL-FIBRILLATION | Fibrinolytic Agents - classification | Recombinant Proteins - therapeutic use | Thiophenes - therapeutic use | Pyrazoles - therapeutic use | Benzylamines - adverse effects | Factor Xa Inhibitors | Anticoagulants - classification | Humans | Thrombin - antagonists & inhibitors | Heparin, Low-Molecular-Weight - therapeutic use | Warfarin - therapeutic use | Fibrinolytic Agents - adverse effects | Rivaroxaban | Pyridines - adverse effects | Angina, Unstable - drug therapy | Prothrombin - antagonists & inhibitors | Hirudins - pharmacokinetics | Morpholines - therapeutic use | Benzimidazoles - therapeutic use | Polysaccharides - therapeutic use | Azetidines - adverse effects | Peptide Fragments - pharmacokinetics | Anticoagulants - therapeutic use | Anticoagulants - adverse effects | Forecasting | Azetidines - therapeutic use | Brain Ischemia - drug therapy | Peptide Fragments - therapeutic use | Benzylamines - pharmacokinetics | Hemorrhage - chemically induced | Heparin - therapeutic use | Recombinant Proteins - pharmacokinetics | Dabigatran | Fibrinolytic Agents - pharmacokinetics | Fibrinolytic Agents - therapeutic use | Thrombosis - prevention & control | Benzimidazoles - adverse effects | Thrombophilia - drug therapy | Pyridines - therapeutic use | Azetidines - pharmacokinetics | Clinical Trials as Topic | Coumarins - therapeutic use | Polysaccharides - pharmacology | Thiophenes - pharmacokinetics | Myocardial Infarction - drug therapy | Anticoagulants - pharmacokinetics | Pyridones - therapeutic use | Thrombosis - drug therapy | Morpholines - pharmacokinetics | Benzylamines - therapeutic use | Physiological aspects | Usage | Warfarin | Heparin
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 12/2015, Volume 373, Issue 25, pp. 2413 - 2424
Journal Article
Journal Article
American Journal of Medicine, The, ISSN 0002-9343, 2014, Volume 127, Issue 11, pp. 1075 - 1082.e1
Journal Article
Journal of the American Academy of Dermatology, ISSN 0190-9622, 08/2017, Volume 77, Issue 2, pp. 356 - 368
Journal Article
American Journal of Cardiology, The, ISSN 0002-9149, 2012, Volume 110, Issue 3, pp. 453 - 460
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 11/2017, Volume 377, Issue 19, pp. 1813 - 1823
In patients with surgically resected melanoma, those with BRAF mutations who received 1 year of oral adjuvant therapy with dabrafenib and trametinib had a 53%... 
HIGH-RISK MELANOMA | SURVIVAL | MEDICINE, GENERAL & INTERNAL | INTERFERON-ALPHA-2B | PLACEBO | THERAPY | MEK INHIBITION | PHASE-III | DOUBLE-BLIND | HAZARD | IPILIMUMAB | Skin Neoplasms - drug therapy | Oximes - adverse effects | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Oximes - therapeutic use | Male | Adjuvants, Immunologic - adverse effects | Young Adult | Melanoma - genetics | Skin Neoplasms - mortality | Aged, 80 and over | Adult | Female | Imidazoles - therapeutic use | Adjuvants, Immunologic - therapeutic use | Skin Neoplasms - surgery | Double-Blind Method | Imidazoles - adverse effects | Pyrimidinones - adverse effects | Pyrimidinones - therapeutic use | Neoplasm Recurrence, Local | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Proto-Oncogene Proteins B-raf - genetics | Melanoma - drug therapy | Skin Neoplasms - genetics | Adolescent | Survival Analysis | Aged | Pyridones - therapeutic use | Melanoma - surgery | Mutation | Neoplasm Staging | Pyridones - adverse effects | Melanoma - mortality | Usage | Relapse | Patient outcomes | Analysis | Melanoma | Adjuvant treatment | Outcome and process assessment (Health Care) | Reports | Drug therapy | Cancer | Diseases | Medical imaging | Oncology | Metastasis | FDA approval | Kinases | Cancer therapies | Survival | Skin cancer | Metastases | Medical prognosis | Immunotherapy | Drug dosages | Index Medicus | Abridged Index Medicus
Journal Article
American Journal of Medicine, The, ISSN 0002-9343, 2015, Volume 128, Issue 12, pp. 1300 - 1305.e2
Journal Article